Video

Dr. Burtness on Immunotherapy and Chemotherapy in Head and Neck Cancer

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

While it unknown if the combination is synergistic, would not necessarily even need to be to be beneficial, says Burtness. A patient could get an independent benefit from immunotherapy and from chemotherapy at the same time, providing the reliability of the chemotherapy response and the durability of the immunotherapy response together.

However, there may be some synergy. Chemotherapy causes DNA damage and cell death and, as the cells die, they release antigens. This creates mutations that may lead to novel antigens. The possibility that there really could be a uniquely synergistic effect, where each drug amplifies the benefit of the other, is very intriguing, says Burtness.

Related Videos
Erminia Massarelli, MD, PhD, MS
Karen L. Reckamp, MD, MS
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Lori Wirth, MD
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School